

## Pharmacy Formulary Updates for July 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in July 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
<b>cholestyramine bulk powder</b>	Excluded
<b>doxepin concentrate</b>	T1;PA (applies to members 12 and younger)
<b>Xodol 5-300 mg</b>	NC;QL
<b>mycophenolate sodium suspension</b>	T2
<b>mycophenolate sodium DR tablets</b>	T2
<b>temozolomide</b>	T2;SP
<b>Lenvima</b>	T2;PA;SP
<b>Rexulti</b>	T3;STPA;QL
<b>levorphanol tartrate 2 mg</b>	NC;QL
<b>Lazanda</b>	NC;QL
<b>Zegerid oral packets</b>	NC;QL
<b>omeprazole/sodium bicarbonate oral packets</b>	T2;PA;QL
<b>omeprazole/sodium bicarbonate capsules</b>	T3;QL
<b>Erleada</b>	NC;SP
<b>Zytiga</b>	NC;QL;SP
<b>Yonsa</b>	NC;SP
<b>methadone concentrate 10 mg/mL</b>	MB
<b>cefixime capsules</b>	T2
<b>Suprax capsules</b>	NC
<b>mesalamine capsules</b>	T2
<b>Delzicol capsules</b>	NC
<b>penicillamine</b>	T2
<b>Cuprimine</b>	NC
<b>erlotinib</b>	T2;QL;SP
<b>Tarceva</b>	NC;QL;SP
<b>Lokelma</b>	T3

<b>Oxervate</b>	T3;PA
<b>Seysara</b>	NC
<b>Yupelri</b>	NC
<b>Bijuva</b>	NC
<b>Entresto</b>	T2
<b>Corlanor</b>	T2
<b>Zinbryta</b>	T3;QL

**Key:**

**MB:** Medical Benefit                    **QL:** Quantity Limitation  
**NC:** Not covered                         **SP:** Specialty Pharmacy - provided  
**NTM:** New-to-market                    through CVS/specialty  
**PA:** Prior Authorization                 **ST:** Step Therapy